166 related articles for article (PubMed ID: 30557221)
1. Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
Dimitriou F; Mangana J; Micaletto S; Braun RP; Dummer R
Melanoma Res; 2019 Feb; 29(1):107-108. PubMed ID: 30557221
[No Abstract] [Full Text] [Related]
2. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
3. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
5. Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?
Kostine M; Stavris C; Chiche L
Eur J Cancer; 2017 Aug; 81():240-241. PubMed ID: 28434854
[No Abstract] [Full Text] [Related]
6. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
7. Immunotherapy toxicity predicted by circulating cytokines.
Gourd E
Lancet Oncol; 2018 Dec; 19(12):e676. PubMed ID: 30449658
[No Abstract] [Full Text] [Related]
8. Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.
Dimitriou F; Mangana J; Dummer R
Acta Derm Venereol; 2020 Jan; 100(1):adv00007. PubMed ID: 31626322
[No Abstract] [Full Text] [Related]
9. Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
Pradère P; Boutros C; Scoazec JY; Dorfmüller P; Leroy-Ladurie F; Boulate D; Le Pavec J; Robert C
Eur J Cancer; 2018 Apr; 93():144-146. PubMed ID: 29402507
[No Abstract] [Full Text] [Related]
10. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
11. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
12. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
[No Abstract] [Full Text] [Related]
13. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
16. Hypopigmented Skin Lesions After Immunotherapy.
Dumbrava EI; Ivan D; Subbiah V
JAMA Oncol; 2018 Aug; 4(8):1118-1119. PubMed ID: 29801033
[No Abstract] [Full Text] [Related]
17. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
18. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
19. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
Mandalà M; Merelli B; Indriolo A; Tondini C
Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189
[No Abstract] [Full Text] [Related]
20. Rash after a single injection of T-VEC.
Wagenknecht D; Kohlmann J; Rütten A; Ziemer M
J Dtsch Dermatol Ges; 2019 Jun; 17(6):649-651. PubMed ID: 30920764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
